The idea for the Hub first came from Huntington Mayor Patrick Farrell soon after taking office in January. He said Tuesday during an appearance on MetroNews Midday he remembers how cold it was and he ...
SARC044: A phase II trial of bezuclastinib in combination with sunitinib in patients with GIST who progressed on sunitinib monotherapy. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Study protocol: Phase 2 trial of re-treatment with 177Lu-PSMA-617 molecular radiotherapy for metastatic castration resistant prostate cancer (RE-LuPSMA trial). Previously presented at ESMO 2024, FPN: ...
-Clinical data to date supports a potentially transformational approach to treating autoimmune diseases with an off-the-shelf, one-time therapy- -As of the August 31, 2025 data cut-off date, all seven ...
Kymera Therapeutics, Inc. (KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral STAT6 protein ...
Kymera's KT-621 shows promising STAT6 degradation in Phase 1 trials, with favorable safety and planned further studies in 2025. KT-621 demonstrated superior Th2 biomarker reductions compared to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results